8-KItem 1.01 · Material AgreementItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Gilead filed exhibits re: an acquisition — Agreement & Plan of Merger (dated Feb 22, 2026) among Gilead,…
Filed with the SEC on · Summarized by InvestorsBot
Gilead filed exhibits re: an acquisition — Agreement & Plan of Merger (dated Feb 22, 2026) among Gilead, Arcellx and Ravens Sub; Form of Tender & Support Agreement; Joint Press Release (Feb 23, 2026). 📄🤝 $GILD #M&A #Biotech
Item 9.01 shows schedules to the merger omitted under Reg S‑K 601(a)(5); Gilead will furnish omitted schedules to the SEC on request. Filing signed by CFO Andrew Dickinson on Feb 23, 2026. 📝 $GILD #SEC #Pharma
Investor takeaway: filing confirms executed merger & tender/support agreements — monitor the joint press release and forthcoming schedules for deal terms, consideration and closing conditions. 🔍 $GILD #M&A #Investing